Dual antiplatelet therapy (DAPT) has been widely used in the treatment of coronary artery diseases, especially in the patients with acute coronary syndrome (ACS) and those after percutaneous coronary intervention (PCI). Data indicate that a significant percentage of individuals treated with clopidogrel do not receive the expected therapeutic benefit because of a decreased responsiveness of their platelets. This phenomenon is called “clopidogrel resistance”. In present years, many studies focused on the effects of types, dosages and combinations of statins and other factors on clopidogrel efficacy, while not enough evidence shows that statins directively and independently affect platelet inhibition by clopidogrel. But these studies provided references for the underlying mechanism of clopidogrel resistance and the interactions between the 2 agents, and furthermore, guided the clinicians to adjust the anti-platelet treatment timely so as to avoid the occurrence of life-threatening thromboembolism. This article summarized the interactions of statins and clopidogrel.